Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients

Journal of Cutaneous Pathology

Volumn 44, Issue 12, 2017, Pages 1080-1086

  Tetzlaff, Michael T ^a   Jazaeri, Amir A ^a   Torres Cabala, Carlos A ^a,b   Korivi, Brinda R ^a   Landon, Genie A ^a   Nagarajan, Priyadharsini ^a   Choksi, Adrienne ^b   Chen, Leon ^b   Uemura, Marc ^a   Aung, Phyu P ^a   Diab, Adi ^a   Sharma, Padmanee ^a   Davies, Michael A ^a   Amaria, Rodabe ^a   Prieto, Victor G ^a,b   Curry, Jonathan L ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Health Science Center at Houston   (United States)

Author keywords

anti CTLA 4; anti PD 1; anti PD L1; dermatologic toxicity; immune checkpoint antibody

Indexed keywords

ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ANTAGONISTS AND INHIBITORS; CASE REPORT; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; DRUG ERUPTION; ERYTHEMA NODOSUM; FEMALE; HUMAN; IMMUNOTHERAPY; METABOLISM; MIDDLE AGED; PANNICULITIS; PATHOLOGY; PROCEDURES; TUMOR RECURRENCE;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CTLA-4 ANTIGEN; DRUG ERUPTIONS; ERYTHEMA NODOSUM; FEMALE; HUMANS; IMMUNOTHERAPY; IPILIMUMAB; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANNICULITIS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85031321571     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.13044     Document Type: Article

References (55)

1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627.
2. Hodi FS. Improved survival with Ipilimumab in patients with metastatic melanoma (vol 363, pg 711, 2010). N Engl J Med. 2010;363(13):1290.
3. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374.
4. Massari F, Santoni M, Ciccarese C, et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev. 2015;41(2):114.
5. McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving Nivolumab. J Clin Oncol. 2015;33(18):2013.
6. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558.
7. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320.
8. Ciccarese C, Alfieri S, Santoni M, et al. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(1):57.
9. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21(8):1712.
10. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15(17):5591.
11. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155.
12. Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69(3):e121.
13. Hwang SJ, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(3):455.
14. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375.
15. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908.
16. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109.
17. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521.
18. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Penas P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015;25(3):265.
19. Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43(8):688.
20. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2016;27(7):1362.
21. Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4(5):383.
22. Chockalingam R, Aung P, Patel AB. Regorafenib-associated panniculitis. Dermatol Online J. 2016;22(6).
23. Choy B, Chou S, Anforth R, Fernandez-Penas P. Panniculitis in patients treated with BRAF inhibitors: a case series. Am J Dermatopathol. 2014;36(6):493.
24. Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA. Panniculitis in patients undergoing treatment with the Bruton tyrosine kinase inhibitor Ibrutinib for lymphoid Leukemias. JAMA Oncol. 2015;1(5):684.
25. Kim GH, Levy A, Compoginis G. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol. 2013;40(7):667.
26. Maldonado-Seral C, Berros-Fombella JP, Vivanco-Allende B, Coto-Segura P, Vazquez-Lopez F, Perez-Oliva N. Vemurafenib-associated neutrophilic panniculitis: an emergent adverse effect of variable severity. Dermatol Online J. 2013;19(4):16.
27. Monfort JB, Pages C, Schneider P, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res. 2012;22(5):399.
28. Mossner R, Zimmer L, Berking C, et al. Erythema nodosum-like lesions during BRAF inhibitor therapy: report on 16 new cases and review of the literature. J Eur Acad Dermatol Venereol. 2015;29(9):1797.
29. Novoa RA, Honda K, Koon HB, Gerstenblith MR. Vasculitis and panniculitis associated with vemurafenib. J Am Acad Dermatol. 2012;67(6):e271.
30. Ramani NS, Curry JL, Kapil J, et al. Panniculitis with necrotizing granulomata in a patient on BRAF inhibitor (Dabrafenib) therapy for metastatic melanoma. Am J Dermatopathol. 2015;37(8):e96.
31. Sinha R, Edmonds K, Newton-Bishop J, Gore M, Larkin J, Fearfield L. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(19):e320.
32. Ugurel S, Lahaye T, Hildenbrand R, et al. Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib. Br J Dermatol. 2003;149(3):678.
33. Vazquez-Osorio I, Sanchez-Aguilar MD, Garcia-Rodino S, Suarez-Penaranda JM, Aliste C, Vazquez-Veiga H. Vemurafenib-induced neutrophilic panniculitis: a new case and review of the literature. Am J Dermatopathol. 2016;38(7):e93.
34. Villani AP, Zaharia D, Dalle S, Depaepe L, Balme B, Thomas L. Vemurafenib-induced panniculitis. Eur J Dermatol. 2013;23(2):258.
35. West ES, Williams VL, Morelli JG. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma. Pediatr Dermatol. 2015;32(1):153.
36. Zimmer L, Livingstone E, Hillen U, Domkes S, Becker A, Schadendorf D. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012;148(3):357.
37. Burillo-Martinez S, Morales-Raya C, Prieto-Barrios M, Rodriguez-Peralto JL, Ortiz-Romero PL. Pembrolizumab-induced extensive panniculitis and nevus regression: two novel cutaneous manifestations of the post-immunotherapy granulomatous reactions Spectrum. JAMA Dermatol. 2017;153(7):721–722.
38. Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158.
39. Tetzlaff MT, Nagarajan P, Chon S, et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features. Am J Dermatopathol. 2017;39(2):121.
40. Birnbaum MR, Ma MW, Fleisig S, et al. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Rep. 2017;3(3):208.
41. Danlos FX, Pages C, Baroudjian B, et al. Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest. 2016;149(5):e133.
42. Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology. 2009;218(1):69.
43. Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract. 2016.
44. Reule RB, North JP. Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol. 2013;69(5):e272.
45. Suozzi KC, Stahl M, Ko CJ, et al. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep. 2016;2(3):264.
46. Tissot C, Carsin A, Freymond N, Pacheco Y, Devouassoux G. Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. Eur Respir J. 2013;41(1):246.
47. Vogel WV, Guislain A, Kvistborg P, Schumacher TN, Haanen JB, Blank CU. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol. 2012;30(2):e7.
48. Wilgenhof S, Morlion V, Seghers AC, et al. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res. 2012;32(4):1355.
49. Timmermans WM, van Laar JA, van Hagen PM, van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Trans Immunol. 2016;5(12):e118.
50. Chaminade A, Conte H, Jouary T, et al. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis. J Eur Acad Dermatol Venereol. 2015;29(2):392.
51. Degen A, Volker B, Kapp A, Gutzmer R. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma. Eur J Dermatol. 2013;23(1):118.
52. Martinez-Rodriguez I, Garcia-Castano A, Quirce R, Jimenez-Bonilla J, Banzo I. Erythema nodosum-like panniculitis as a false-positive 18F-FDG PET/CT in advanced melanoma treated with Dabrafenib and Trametinib. Clin Nucl Med. 2017;42(1):44.
53. Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med. 2006;354(24):2623.
54. Pincus LB, LeBoit PE, McCalmont TH, et al. Subcutaneous panniculitis-like T-cell lymphoma with overlapping clinicopathologic features of lupus erythematosus: coexistence of 2 entities? Am J Dermatopathol. 2009;31(6):520.
55. Wenzel J, Proelss J, Wiechert A, Zahn S, Bieber T, Tuting T. CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus. J Am Acad Dermatol. 2007;56(4):648.